Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials
Academic Article
Overview
MeSH Major
Antibodies, Monoclonal
Neoplasms
abstract
This retrospective analysis of five placebo-controlled clinical trials does not support a decreased time to disease progression, increased mortality, or altered disease progression pattern after cessation of bevacizumab therapy.
